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Abstract
Current clinical delivery of recombinant human bone 
morphogenetic proteins (rhBMPs) utilises freeze-dried 
collagen. Despite effective new bone generation, rhBMP 
via collagen can be limited by significant complications 
due to inflammation and uncontrolled bone formation. 
This study aimed to produce an alternative rhBMP local 
delivery system to permit more controllable and superior 
rhBMP-induced bone formation. Cylindrical porous 
poly(lactic-co-glycolic acid) (PLGA) scaffolds were 
manufactured by thermally-induced phase separation. 
Scaffolds were encapsulated with anabolic rhBMP-2 
(20 µg) ± anti-resorptive agents: zoledronic acid (5 µg ZA), 
ZA pre-adsorbed onto hydroxyapatite microparticles, (5 µg 
ZA/2 % HA) or IkappaB kinase (IKK) inhibitor (10 µg 
PS-1145). Scaffolds were inserted in a 6-mm critical-
sized femoral defect in Wistar rats, and compared against 
rhBMP-2 via collagen. The regenerate region was examined 
at 6 weeks by 3D microCT and descriptive histology. 
MicroCT and histology revealed rhBMP-induced bone 
was more restricted in the PLGA scaffolds than collagen 
scaffolds (-92.3 % TV, p < 0.01). The regenerate formed 
by PLGA + rhBMP-2/ZA/HA showed comparable bone 
volume to rhBMP-2 via collagen, and bone mineral density 
was +9.1 % higher (p < 0.01). Local adjunct ZA/HA or 
PS-1145 significantly enhanced PLGA + rhBMP-induced 
bone formation by +78.2 % and +52.0 %, respectively 
(p ≤ 0.01). Mechanistically, MG-63 human osteoblast-like 
cells showed cellular invasion and proliferation within 
PLGA scaffolds. In conclusion, PLGA scaffolds enabled 
superior spatial control of rhBMP-induced bone formation 
over clinically-used collagen. The PLGA scaffold has the 
potential to avoid uncontrollable bone formation-related 
safety issues and to customise bone shape by scaffold 
design. Moreover, local treatment with anti-resorptive 
agents incorporated within the scaffold further augmented 
rhBMP-induced bone formation.
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Introduction
Recombinant human bone morphogenetic proteins 
(rhBMPs) are commonly used as primary osteoinductive 
growth factors in orthopaedics and are being increasingly 
adopted as alternatives to bone graft. The clinical standard 
is to use purified collagen scaffolds for local rhBMP-2 
delivery. Although, collagen is able to bind and retain 
BMPs, there is a significant burst release resulting in initial 
high local concentrations. This could lead to increased 
osteoclastogenesis (Itoh et al., 2001; Kaneko et al., 2000) 
and premature or exuberant bone resorption (Pradhan et 
al., 2006). A recent systematic clinical review highlighted 
how rhBMP delivery via collagen can be limited by both 
poorly controlled and ectopic bone formation (Carragee 
et al., 2011). Collagen scaffolds are also described as 
having inferior scaffold biomechanics and are limited 
by the potential low risk of prion-disease (DeLustro et 
al., 1990). In contrast, synthetic biomaterials have the 
advantages of relative ease of manufacturing, a lack 
of an immune response, and no risk of disease transfer 
(DeLustro et al., 1990; Geesink et al., 1999; Kato et 
al., 2006; Olsen et al., 2003). Inorganic ceramics are 
limited by the material’s brittleness, stiffness, and poor 
material strength, which restrict the shape of the scaffold. 
Furthermore, these materials have poor biodegradation 
rates and material radiopacity, which can complicate 
bone-healing assessment (Yu et al., 2010a).
 Biodegradable poly(α-hydroxy acids) polymers are 
emerging as a promising alternative biomaterial for local 
BMP delivery over inorganic ceramics and inorganic 
non-ceramics. One such example is poly(D,L-lactic-
co-glycolic acid) (PLGA), which is associated with an 
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extensive FDA approval history, superior biocompatibility, 
the potential for controlled drug release, controlled 
degradation rate, and mouldable form (Sokolsky-Papkov 
et al., 2007). To improve poly(α-hydroxy acids)-based 
polymer biocompatibility, hydroxyapatite (HA) particles 
have been added (Maquet et al., 2004; Maquet et al., 
2003), since the acidic degradation products of PLGA can 
result in a local decrease in pH and an increase in tissue 
inflammation around the implant (Yu et al., 2010a).
 Thermally-induced phase-separation (TIPS) is a 
solvent-based polymer scaffold fabrication technique 
for the production of highly porous scaffolds with 
interconnected pores, which are scaffold characteristics 
crucial for cell migration, oxygen and nutrient supply to 
cells, waste transfer, and tissue in-growth (Hollister, 2005; 
Mooney et al., 1994). TIPS fabrication allows tailored 
pores size and distribution by controlling the cooling/
quenching regime (i.e. quenching rates and quenching 
temperature) (Cao et al., 2004a; Cao et al., 2004b). In a 
precursor study (Yu et al., 2013), we employed a TIPS 
quenching protocol for the local delivery of rhBMP-2. The 
resulting 90 % porous PLGA matrix with highly ordered 
cellular pore structures and high interconnectivity showed 
superior bone-forming capacity and degradation over slow 
degrading poly(dl)-lactide (Yu et al., 2013).
 Our bone tissue engineering strategy is consistent with 
the Diamond Model for fracture healing, which proposes 
that an optimal bone formation outcome is dependent 
on the selection of type of scaffold or matrix, growth 
factors, populations(s) of osteogenic cells, and the amount 
of mechanical loading (Giannoudis et al., 2007). We 
previously induced ectopic bone formation in a murine 
model by implantation of TIPS-fabricated PLGA porous 
scaffold containing rhBMP-2 (Yu et al., 2013). The local 
delivery muscle implantation model harnessed the bone-
forming abilities of endogenous osteoprogenitors that are 
stimulated to form bone with rhBMP-2. To avoid impaired 
bone formation due to local resorptive forces stimulated 
by high local rhBMP concentrations (Itoh et al., 2001; 
Kaneko et al., 2000), rhBMP was encapsulated in our 
PLGA scaffolds for slow and sustained local delivery (Yu 
et al., 2013).
 When using rhBMPs to induce bone formation in a 
critical-sized defect or ectopic bone formation model, the 
newly formed bone is often protected from mechanical 
loading (i.e. stress-shielded). This can lead to premature 
bone resorption (Wolff, 1892). Consequently, our bone 
tissue engineering strategy aims to modulate both bone 
formation and bone resorption (Little et al., 2005; Yu et 
al., 2012). This study employs agents from two classes 
of anti-resorptives: bisphosphonates and IkappaB kinase 
(IKK) inhibitors. Bisphosphonates are routinely used 
for the treatment of osteoporosis and other metabolic 
bone disorders. Nitrogen-containing bisphosphonates 
(e.g. pamidronate, alendronate, risedronate, ibandronate, 
and zoledronic acid) inhibit farnesyl pyrophosphate 
(FPP) synthase, which leads to cellular dysfunction in 
osteoclasts (Russell et al., 2007). As reviewed by Yu et al. 
(2012), numerous pre-clinical studies have demonstrated 
synergy between rhBMPs and bisphosphonates delivered 
systemically or locally.
 To further augment bone formation in a BMP/ZA 
co-delivery system, a calcium phosphate-based material, 
such as hydroxyapatite microparticles (HA) could be 
considered. HA has demonstrated both osteoconductive 
and anti-inflammatory potential (Calandrelli et al., 2004; 
Rezwan et al., 2006). Furthermore, zoledronic acid (ZA) 
has a known affinity to bind to calcium phosphates (in 
both natural and synthetic forms) and ZA/HA could be 
preferentially phagocytosed by osteoclasts (Coathup et 
al., 2001). Emerging anti-resorptive agent, IKK-inhibitor 
(PS-1145) has been found to induce apoptosis in osteoclast 
precursors, as well as inhibit osteoclastogenesis and bone 
erosion (Idris et al., 2010; Idris et al., 2009; Ruocco et al., 
2005) and shown potential in augmenting rhBMP-induced 
bone tissue engineering (Carr et al., 2011).
 This study aims to produce an alternative rhBMP local 
delivery system to a collagen-based system, which permits 
superior and more controllable rhBMP-induced bone 
formation. This study utilised a rat critical defect model 
that does not heal without anabolic intervention (Little et 
al., 2005). As a secondary aim to test the effects of co-
delivery of anabolic and anti-resorptive agents, we inserted 
porous scaffolds containing rhBMP-2/ZA or rhBMP-2/
IKK inhibitor PS-1145. Direct comparisons with current 
collagen-based technologies were used to demonstrate 
improved bone formation and bone retention, leading to 
more robust union.
Materials and Methods
Reagents
Recombinant human bone morphogenetic protein-2 
(rhBMP-2) from the Infuse® Bone Graft Small Kit 
was purchased from Medtronic (Memphis, TN, USA). 
Zoledronic acid (ZA) was purchased from Axxora LLC 
(San Diego, CA, USA). IKK-inhibitor PS-1145 (>98 % 
HPLC) was purchased from Sigma Aldrich (Sydney, 
Australia). Poly(D,L-lactide-co-glycolide) (PLGA) 
biodegradable polymer (lactide:glycolide ratio of 50:50 and 
inherent viscosity 0.95-1.20 dL/g, Durect, Lactel©, Pelham, 
AL, USA) and solvent 1, 4-dioxane (99 % ACS reagent, 
Ajax Finechem Pty Ltd, Taran Point, Australia) were used 
for the fabrication of porous PLGA scaffolds. Collagen 
from the Infuse® Bone Graft Small Kit was used as 
supplied. Precalcined hydroxyapatite (HA) microparticles 
with an average diameter ≈1.5 µm were used (P149, Plasma 
Biotal Ltd, Derby, UK). Particles were agglomerates of 
acicular nanoparticles (diameter ≈100 nm x 250 nm) (Ruys 
et al., 1995). ZA was adsorbed to HA following the protocol 
previously published by Yu et al. (2013). Briefly, ZA/sterile 
water solution (1 mg/mL) was incubated with HA (37 °C 
water bath for 24 h), filtered, and the remaining ZA/HA 
vacuum-dried (for 8 h at -70 kPa and 45 °C).
Drug-loaded polymer scaffold fabrication
Porous PLGA scaffolds containing 20 μg rhBMP-2 ±5 μg 
ZA ± HA were fabricated by thermally induced phase 
separation (TIPS) methods as described previously (Yu 
et al., 2013). In brief, a PLGA/dioxane stock solution 
was diluted with dioxane-containing drug ± HA solutions 
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to give a final concentration of 10 % w/v. The polymer 
solution and drug/dioxane suspensions were generated 
by mixing dioxane with polymer pellets or drugs by 
weight by vortex and sonication. These solutions were 
then combined and further mixed by vortex to yield the 
appropriate polymer and drug concentrations. Composite 
HA/PLGA scaffolds were loaded with HA at 2 % w/w. 
The final solutions were transferred into glass moulds and 
quenched at a controlled rate -0.5 °C/min from 25 °C to 
-10 °C. The quenched scaffold rods were removed from 
glass moulds and placed under high vacuum for solvent 
removal (8 h, –7.3 x 10-4 mbar). Vacuum-dried scaffold 
rods were sliced transversely with a stainless steel blade 
into 1 mm thick disks or 5 mm long cylinders. For cell 
culture experimentation, scaffold dimensions were 3 mm 
diameter x 1 mm height. For surgical insertion, scaffolds 
dimensions were 3 mm diameter x 5 mm height. Scaffold 
drug doses followed Table 1 and Table 2. The scaffolds 
were UV sterilised (5 min) prior to surgical insertion and 
cell culture.
Drug-loaded collagen scaffold preparation
Porous collagen scaffolds were cut to size (5 mm x 5 mm) 
under sterile conditions from collagen sheets (4 mm 
thickness) supplied from the Infuse® Bone Graft Small Kit. 
Each scaffold was loaded with 20 μg rhBMP-2 solution 
(i.e. 20 μL x 1 mg/mL). Following the manufacturer’s 
instructions, the rhBMP-2 solution was applied to the 
scaffold 20 min prior to surgical insertion.
Cell viability analysis
MG-63 cells, a human osteoblastic cell line, were cultured 
in α-MEM supplemented with 10 % foetal bovine serum, 
1 % L-glutamine and 2 % penicillin/streptomycin. Media 
were changed every 4 d and cells were removed from flasks 
using trypsin-EDTA solution. Cell number was calculated 
using a haemocytometer to produce a 3 x 106 cells/mL cell 
suspension.
 Drug loaded-PLGA scaffolds (Table 1) were placed in 
48-well plates and seeded with 5 µL of a 3 x 106 cells/mL 
cell suspension followed by a 15 min incubation period. 
The scaffold was then turned over and 5 µL of the cell 
suspension was seeded on the opposite side. This was 
incubated for a further 15 min. The wells were then flooded 
with 500 µL of standard growth medium. Cell free PLGA 
scaffolds served as negative controls.
 At 3 d and 7 d post seeding, cellular viability was 
assessed using the CellTitre 96 Aqueous One Solution 
Cell Proliferation Assay kit (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions. Briefly, 
scaffolds were incubated with the viability solution for 
30 min at 37 °C and read using a spectrophotometer at 
595 nm. All samples were assayed in triplicate and the 
results are representative of n = 6 scaffolds.
 At day 7, cell-scaffolds were stained with fluorescent 
DAPI (15 min in 0.02 μg, 4’,6-DAPI, diamidino-2-
phenylindole), washed with phosphate-buffered saline 
(PBS, 10 min), and halved transaxially with a stainless steel 
surgical blade. Representative transaxial scaffold sections 
were captured with a Leica TCS SP5 confocal microscope 
(Leica Microsystems, Wetzlar, Germany). DAPI-stained 
cells were visualised with the 405 nm laser (emission 
410-470 nm) and scaffold autofluorescence was visualised 
with the 488 nm laser line of the argon laser (emission 
500-570 nm). Sections were scanned with a 10x objective 
using the Tile Scan (2 x 5 image array) and the Z-Stack 
functions (4 sections at 20 μm intervals) for a total of 40 
images per scaffold. Maximum intensity projections were 
done with Leica Application Suite Advanced Fluorescence 
software (Version 2.5.1-6757, Leica Microsystems).
Animal care
Male Wistar rats were purchased from the Animal 
Resources Centre (Perth, Australia) and used at 12 weeks 
(average weight of 440 g). Animals were allowed 1-week 
acclimatisation to local vivarium conditions prior to 
surgery. Animal studies were approved by the local animal 
ethics committee (AEC #5068) and animals were given 
chow and water ad libitum.
Table 1. Cell viability experimental design.
Group ID Scaffold Anabolic agent Anti-catabolic agent n
PLGA PLGA polymer scaffold - - 6
PLGA + BMP PLGA polymer scaffold 4 µg BMP-2 - 6
PLGA + BMP/ZA PLGA polymer scaffold 4 µg BMP-2 1 µg ZA 6
PLGA + BMP/ZA/HA PLGA polymer scaffold 4 µg BMP-2 1 µg ZA via HA 6
PLGA + BMP/PS-1145 PLGA polymer scaffold 4 µg BMP-2 20 µg PS-1145 6
Table 2. Surgical experimental design.
Group ID Scaffold Anabolic agent Anti-catabolic agent n
PLGA PLGA polymer scaffold - - 5
PLGA + BMP PLGA polymer scaffold 20 µg BMP-2 - 20
PLGA + BMP/ZA PLGA polymer scaffold 20 µg BMP-2 5 µg ZA 20
PLGA + BMP/ZA/HA PLGA polymer scaffold 20 µg BMP-2 5 µg ZA via HA 20
PLGA + BMP/PS-1145 PLGA polymer scaffold 20 µg BMP-2 100 µg PS-1145 20
COL + BMP Collagen scaffold 20 µg BMP-2 - 20
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Surgical insertion of scaffold into rat critical defect
A well-described rat femoral critical defect model was 
used (Little et al., 2005). Anaesthesia was induced with 
an intraperitoneal injection of 75 mg/kg ketamine and 
10 mg/kg xylazine. A lateral approach to the right femur 
was made and the periosteum stripped. A polyacetyl plate 
(27 × 4 × 4 mm) was fixed to the femur with four 1 mm 
threaded Kirschner wires and two 1 mm surgical steel 
circlage wires passing through pre-fashioned notches in 
the plate. A 6 mm critical-sized full-thickness defect was 
created in the diaphysis with an oscillating saw and the 
bone was stabilised by the plate (Fig. 1A). The defect was 
inserted with porous PLGA scaffold loaded with various 
drug combinations: BMP-2, BMP/ZA, BMP/ZA/HA, or 
BMP/PS-1145 (n = 20/scaffold group). As a clinical BMP 
control, the defect was also inserted with BMP-2 delivered 
via collagen (n = 20). A PLGA scaffold alone group served 
as a negative control (n = 5) (Table 2).
 The scaffolds were secured in place by threading two 
sutures (4/0 Vicryl suture, Ethicon, Sommerville, NJ, USA) 
through the scaffold’s centre and securing the suture around 
the plate (Fig. 1B). The wound was closed with 4/0 Vicryl 
suture and 2 mL sterile saline was given subcutaneously 
as fluid replacement. Animals were given analgesia with 
buprenorphine (0.05 mg/kg) and monitored for pain. Bone 
repair occurred over the following 6 weeks and rats were 
monitored by weekly X-ray and weighing. To assess bone 
formation using fluorochrome labelling, calcein (10 mg/
kg) was administered by subcutaneous injection at 10 and 
3 d prior cull. After 6 weeks post-operatively, animals were 
euthanised and whole femora were harvested post-mortem. 
Samples were fixed in 4 % paraformaldehyde, and stored 
in 70 % ethanol for radiographic and histological analysis.
Radiological micro-computed tomography 
(microCT)
Three-dimensional (3D) bone measurement was carried out 
by microCT. Samples were scanned in 70 % ethanol with 
SkyScan 1174 compact μCT scanner (SkyScan, Kontich, 
Belgium) at 14.7 μm pixel resolution and with 0.5 mm 
aluminium filter, 50 kV X-ray tube voltage, 800 μA tube 
electric current, and 4500 ms scanning exposure time. 
MicroCT images were reconstructed using NRecon (version 
1.6.1.7, SkyScan) and three dimensional assessments were 
conducted with CTAnalyser software (version 1.12.10.3, 
SkyScan). The primary outcome measurement was bone 
volume (BV, mm3) of the regenerate using 250 slices that 
encompassed a 3.712 mm central region of the defect. 
The rationale for selecting this region of interest was to 
minimise variation due to differences in defect height such 
that a consistent length of regenerate was selected. Notably, 
scaffold-bone integration at the implant boundaries was 
independently assessed by means of histology. Secondary 
outcome measurements included bone tissue alone mineral 
density (bone TMD, g/cm3). The bone tissue was defined as 
calcified tissue detected by microCT using a predetermined 
global threshold set at 0.4 g/cm3. Bone tissue mineral 
density (bone TMD, g/cm3) was as defined by Bouxsein 
et al. (2010) as the material density of bone tissue region 
only. The total volume of regenerate tissue formed within 
the critical defect (TV, mm3) was also quantified using 
microCT. Bone formed outside of the critical defect space 
relative to the critical defect space was calculated as the 
excess regenerate (%).
 Bone union grading was further assessed by a single 
operator blinded to intervention using 3D maximum 
intensity projection reconstructions were generated using 
CTAnalyser software (version 1.12.10.3, SkyScan). 
Defects were graded as being united (4 cortices in two 
planes), partially united (2-3 cortices in two planes), or 
not united.
 Samples were excluded by a single operator blinded 
to intervention as determined by two-dimensional X-ray 
(27 kV and 2x magnification, MX 20 Digital Camera, 
Faxitron X-ray Corp, Wheeling, IL, USA) and 3D microCT 
maximum intensity projections. There were five anaesthetic 
deaths, two infections, and two cases of loss of fixation 
due to slipped plates. Eight specimens were excluded due 
to misalignment of implant with bone ends such that one 
or both ends of the implant were no longer in the defect. 
Fig. 1. (A) Fixation of a 6 mm critical-sized femoral defect with plate and wires, and (B) insertion of a scaffold into 
the bone defect. Arrowhead points towards a PLGA polymer scaffold.
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The final group sizes were n = 19 (BMP + COL), n = 17 
(PLGA + BMP), n = 15 (PLGA + BMP/ZA), n = 17 (PLGA 
+ BMP/ZA/HA), n = 15 (PLGA + BMP/PS-1145) and n = 5 
(PLGA only).
Histological analysis
Histology was conducted on n = 10 samples for the 
rhBMP-2 loaded scaffold groups and n = 5 for the PLGA 
scaffold control group. Animals were prospectively 
assigned to histology endpoints prior to surgery. Fixed 
bone samples were processed and embedded undecalcified 
in resin for histological sectioning. The right femur of each 
rat was sliced longitudinally from the middle and serial 
sections of 0.5 μm thick were stained with Von Kossa stain 
for bone mineral. The integration of regenerate region with 
ends of the old cortex was assessed on sections stained 
with Goldner’s trichrome. Osteoclasts were identified on 
sections stained for tartrate-resistant acid phosphatase 
(TRAP).
 Images were captured with a ScanScope digital slide 
scanner (Aperio Technologies, Inc, Vista, CA, USA), 
and visualised with ImageScope software (Aperio 
Technologies). Calcein-flurochrome labelled bone 
sections were visualised and captured using a Leica 
TCS SP5 confocal microscope (Leica Microsystems). 
Calcein-labelled bone was visualised with the 488 nm 
line of the argon laser (emission 500-560 nm) and tissue 
autofluorescence was visualised at 561 nm (emission 570-
670 nm) with the DPSS 561 laser. Sections were scanned 
with a 10x objective using the Tile Scan (200 images) 
and Z-Stack (5 sections at 10 μm steps) functions. Post 
image processing was done with Leica Application Suite 
Advanced Fluorescence software (Version 2.5.1-6757, 
Leica Microsystems).
 For each osteointegration analysis, a total of four 
regions representing the scaffold/cortex interfaces were 
assessed as illustrated in Fig. 2. The scaffold integration 
grading system was as follows: 0 points (fibrous tissue, 
i.e. scaffold not bridged with cortex), 1 point (cartilage, 
i.e. scaffold partially bridged with cortex), and 2 points 
(mineralised tissue, i.e. osteoid completely bridged with 
cortex).
Statistical analyses
Statistical analysis of microCT data was conducted with 
non-parametric statistical tests (Kruskal Wallis and Mann 
Whitney U), as process of bone formation and union could 
not be assumed to follow a normal distribution. Statistical 
analyses of cell viability data comparison between scaffold 
groups was conducted with one way ANOVA and post-hoc 
with Dunnett’s t-test. Statistical analyses of cell viability 
data comparison between 3 d or 7 d post-seeding within 
each group was conducted with paired t-test. Tests were 
performed using SPSS Statistics version 21 (SPSS Inc., 
Chicago, IL, USA). Statistical significance was set at 
p < 0.05.
Results
Cell attachment, proliferation and migration in 
porous PLGA scaffolds
To determine the ability of the drug loaded PLGA scaffolds 
to facilitate MG-63 cell attachment and proliferation, cell 
viability was determined at days 3 and 7 post seeding. 
Cell viability was maintained in all scaffold groups at 
both time points. There were no significant differences in 
cell viability between any of the scaffold groups at either 
time point, but between 3 and 7 d significant cell growth 
was noted in all groups (p < 0.01, Fig. 3A) indicating 
the scaffolds were biocompatible. Following 7 d post 
seeding, scaffolds were stained with DAPI and examined 
using confocal microscopy to investigate the distribution 
of the cells within the scaffolds. DAPI-positive staining 
was observed in all the scaffold groups. Although cell 
aggregations formed along the edges of the scaffolds, cells 
Fig. 2. Representative micrograph illustrating 4 scaffold/cortex regions (R1 to R4) used to assess scaffold integration.
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fully penetrated the scaffolds 7 d post seeding (Fig. 3B). 
This was observed in all the scaffold types regardless of 
drug treatment.
3D bone healing and bone formation analyses
3D microCT was used to assess the bone healing-potential 
of the PLGA scaffolds in a critical-sized bone defect. The 
union rate was assessed by a single operator blinded to 
intervention. The region of interest assessed for the union 
rate included 3D microCT reconstructions of the regenerate 
region and surrounding cortices. Bone formation in the 
regenerate region was quantified by bone volume (BV, 
mm3) and bone tissue alone mineral density (bone TMD, 
g/cm3 of calcium hydroxyapatite).
 3D microCT reconstructions of the regenerate and 
surrounding cortices were used to assess the union rate. 
The highest union rate was found with PLGA + BMP/
ZA/HA co-treatment (94 % complete unions), followed 
by PLGA + BMP/PS-1145 co-treatment (87 % complete 
unions). BMP delivery via COL and PLGA systems led 
to 68 % and 53 % complete unions, respectively. Finally, 
PLGA + BMP/ZA led to 47 % complete unions (Fig. 4).
 3D bone formation was quantified by bone volume 
(BV, mm3) and bone tissue mineral density (bTMD, g/cm3) 
at the regenerate region (Fig. 5). Local BMP/ZA/HA co-
treatment significantly increased bone volume over PLGA 
+ BMP control (+78.18 %, p < 0.01) and was comparable 
to COL + BMP control (+20.16 %, p = 0.27) (Fig. 5A). 
However, local BMP/ZA did not significantly change bone 
volume compared to PLGA + BMP control (+16.96 %, 
p = 0.56) and showed significantly lower bone volume 
compared to COL + BMP control (-21.13 %, p = 0.046). 
Local BMP/PS-1145 co-treatment significantly increased 
bone volume compared to PLGA + BMP control (52.0 %, 
p = 0.01), but not when compared to COL + BMP control 
(+2.49 %, p = 0.62). Finally, COL + BMP had higher bone 
volume compared to PLGA + BMP (+48.3 %, p < 0.01).
 The 3D bone tissue mineral density (bTMD, g/cm3) 
was assessed at the regenerate region (Fig. 5B). Compared 
with COL + BMP, regenerate bone density was higher in 
local PLGA + BMP treatment (+4.94 %, p = 0.04) and 
co-treatment with ZA or ZA/HA (+8.45 %, p = 0.03 and 
+9.12 %, p < 0.01). Local co-treatment with PLGA + BMP/
PS-1145 led to comparable bone density to COL + BMP.
Three-dimensional spatial control of bone formation
2D and 3D microCT reconstructions of the regenerate 
region and the adjacent original cortex were generated 
to visually compare implant-interface boundary and the 
production of bone outside the original scaffold template 
(Fig. 6). Defects treated with PLGA scaffold in the absence 
of rhBMP-2 did not induce bone formation and were thus 
graded as having no integration.
 The microCT reconstructions demonstrated greater 
restriction of rhBMP-2-induced bone formation in the 
porous PLGA scaffold groups as illustrated by coronal 
2D slices (Fig. 6A) and 3D maximum intensity projection 
reconstructions (Fig. 6B coronal and Fig. 6C transaxial). 
MicroCT quantification confirmed PLGA scaffold led to 
a greater spatial control of rhBMP-2-induced bone, with 
a significantly lower regenerate tissue volume (TV, mm3) 
over COL + BMP treatment, (-65.9 % TV, p < 0.01). In 
Fig. 3. (A) Cell viability of 
MG-63 seeded onto scaffold 
at day 3 and day 7. *p < 0.01 
increase vs. day 3 (B) MG-63 
cell (blue) proliferation through 
a mid-transaxial plane of a 
scaffold (green) at day 7.  Scale 
bar = 500 μm.
Fig. 4. Radiographic assessment of bone union at 6 
weeks.
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Fig. 5. Bone formation analysis at regenerate region measured at 6 weeks post-operatively. (A) Bone volume (BV, 
mm3) and (B) bone tissue mineral density (bone TMD, g/cm3). #p < 0.05 decrease vs. COL + BMP, ##p < 0.05 increase 
vs. COL + BMP, *p < 0.05 decrease vs. PLGA + BMP, **p < 0.05 increase vs. PLGA + BMP.
Fig. 6. Reconstructions of healed critical-sized defects at 6-weeks post-operatively. The cortex and regenerate are 
shown as (A) 2D coronal slices and (B) 3D reconstructions. The regenerate region is shown as (C) 3D reconstructions.
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Fig. 7. Regenerate region spatial control measured at 6 weeks post-operatively. (A) Regenerate tissue volume (TV, 
mm3) and (B) excess regenerate percentage (%). #p < 0.01 decrease vs. COL + BMP and **p < 0.01 decrease vs. 
PLGA + BMP.
Fig. 8. Representative micrographs of bone defects at 6-weeks. (A and A’) Goldner’s Trichrome-stained sections, 
(B and B’) von Kossa-stained sections, and (C and C’) calcein (green) labelling performed at 10 and 3 d prior to 
end of study. Scale bar = 1 mm.
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some cases, this led to an apparently inferior implant-
interface osseointegration compared to collagen, and 
this was further explored in histological sections. Images 
shown represent specimens closest to the mean BV for 
each treatment group.
 As an alternate measure of spatial control, the tissue 
volume of the regenerate (TV, mm3), was quantified by 
microCT. The rhBMP-2-induced bone was compared 
between PLGA and COL local delivery systems. The 
excess regenerate as a percentage of the defect space was 
considerably greater in the collagen group compared to the 
PLGA groups (Fig. 7).
Histology
Histological slices of the regenerate and cortex were 
stained with Goldner’s trichrome and von Kossa to 
visualise mineralised bone matrix (Fig. 8). Calcein 
fluorochrome-labelled bone was used to compare the bone 
retention/turnover with PLGA + BMP/anti-resorptive co-
treatment with COL + BMP. Increased mineralised bone 
matrix of regenerate region was shown in PLGA + BMP/
ZA ±HA group compared with BMP delivered via collagen 
or via PLGA (Figs. 8A and B). Defects treated with BMP/
PS-1145 co-treatment also showed increased bone density 
of regenerate compared with BMP + PLGA treatment. 
Finally, calcein fluorochrome-labelled bone showed greater 
labelling (i.e. higher bone retention) in PLGA + BMP/ZA/
HA treated defects compared with PLGA + BMP/anti-
resorptives (ZA or PS-1145) and COL + BMP (Fig. 8C), 
indicating lower bone turnover in PLGA + BMP/ZA/HA 
compared to other treatment groups.
 Goldner’s trichrome-stained samples were used to 
assess the scaffold-implant integration using a scoring 
system for the four cortices in two planes. There was a 
trend towards reduced integration at the interface with 
rhBMP-2 and rhBMP-2/ZA PLGA groups versus collagen 
delivery, however, the trend was not significant (p = 0.49 
and p = 0.39, respectively). The rhBMP-2/PS1145 and 
rhBMP-2/ZA/HA groups were comparable to collagen 
(Fig. 9). Statistical analyses showed that only the rhBMP-2/
ZA/HA group showed significantly greater integration 
than rhBMP-2 PLGA controls (p = 0.02). While rhBMP-2/
PS1145 showed a trend towards increased integration 
versus rhBMP, it did not reach significance (p = 0.26 vs. 
COL + rhBMP) with a post-hoc power analysis indicating 
the potential for type II error.
Discussion
The healing of critical-sized defects is often complicated 
by premature and/or excessive bone resorption caused 
by stress-shielding, instability, or inflammation/infection 
(Amanat et al., 2005). These challenges associated with 
resorption can be aggravated by rhBMP treatments, which 
can promote osteoclastic resorption (Itoh et al., 2001; 
Kaneko et al., 2000; Pradhan et al., 2006). Thus numerous 
pre-clinical studies have investigated the efficacy of 
modulating rhBMP-induced bone formation with adjunct 
anti-resorptive agents, such as bisphosphonates (Belfrage 
et al., 2011; Chen et al., 2004; Chen et al., 2006; Jakobsen 
et al., 2007; Jakobsen et al., 2010; Jeppsson et al., 2003; 
Little et al., 2005; Yu et al., 2010b; Yu et al., 2013). 
IKK inhibitors such as PS-1145 also show promise for 
maximising rhBMP-induced bone formation (Carr et al., 
2011).
 Incorporation of small molecule inhibitors of bone 
resorption into classical collagen scaffolds can be 
challenging. Acellular collagen scaffolds are able to bind 
and retain BMPs, although there is still a significant burst 
release. A recent systematic clinical review (Carragee et 
al., 2011) emphasised the limitations of rhBMP delivery 
via collagen, including poorly controlled and ectopic bone 
formation. Moreover, the review highlighted the potential 
benefits of modulating the rhBMP delivery rate using 
alternate carriers (Carragee et al., 2011). In light of the 
limitations of porous collagen, there has been previous 
research in this area (Brown et al., 2011; DeLustro et al., 
1990; Geesink et al., 1999; Kato et al., 2006; Olsen et al., 
2003).
 We have previously utilised this porous PLGA scaffold 
as an alternative local rhBMP delivery system able to co-
deliver anti-resorptives in simple ectopic bone formation 
model (Yu et al., 2013). In this study, we demonstrated 
superior rhBMP-2 induced bone formation with local 
adjunct anti-resorptive ZA adsorbed HA microparticles, 
when compared with PLGA + BMP-2 and PLGA + 
BMP-2/ZA. Compared to the clinical gold standard of 
collagen, PLGA scaffolds showed a delayed rhBMP-2 in 
vitro release profile. Moreover, the adsorption of ZA onto 
HA microparticles further reduced ZA release from PLGA 
scaffolds without altering rhBMP-2 release.
 In light of these data, this study aimed to employ a 
more complex and clinically-relevant rat femoral critical-
sized defect surgical model. It first aimed to demonstrate 
Fig. 9. The average scaffold/cortex integration grades at 
6 weeks post-operatively. *p = 0.02 vs. PLGA + BMP.
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the efficacy of a porous PLGA biodegradable scaffold as 
an alternative rhBMP delivery system with greater spatial 
control of new bone formation. Secondly, this study aimed 
to further modulate PLGA + rhBMP scaffold-induced 
critical-sized defect healing with local adjunct anti-
resorptive agents, zoledronic acid (ZA) or IKK-inhibitor 
(PS-1145).
 The porous PLGA scaffold presented in this study 
facilitated greater spatial control of rhBMP-induced 
bone formation over clinically used collagen scaffold. 
This is most obvious in radiographic images/microCT 
reconstructions where the COL control group showed 
new bone that formed considerably away from the original 
cortex. While the volume of the regenerate in the COL 
group was considerably greater, the measured bone volume 
was only ~50 % higher, and histology showed the COL 
group to be filled with a substantive pseudo marrow cavity. 
In contrast, the PLGA scaffold showed a higher density 
and more trabecular-like bone (Fig. 8). The mechanism 
for this more restricted control may be associated with the 
altered release rate of rhBMPs, which has been previously 
shown comparing this PLGA implant to collagen (Yu et al., 
2013). Development of this system may allow for reduced 
clinical complications associated with uncontrolled 
bone formation, including unwanted ossification of the 
surrounding tissues and neural impingement (Carragee et 
al., 2011). In addition, with specialised mould geometry, 
bone of customized shapes and sizes might be generated.
 The co-delivery of anti-resorptives and/or ceramic 
microparticles led to significant increases in union rate 
and in bone volume. This is consistent with our prior 
findings showing enhancement of rhBMP-2 action with 
bisphosphonates in an ectopic bone model using this 
PLGA carrier (Yu et al., 2013). The doses selected for 
this critical defect study were comparable in terms of 
drug concentration per unit scaffold with this prior study, 
although the implant size was larger. The addition of anti-
resorptive drugs did not adversely affect osteoblastic cells 
in vitro in terms of viability or migration into the implants. 
Moreover, while the breakdown products of PLGA are 
acidic and have the potential to cause inflammation, there 
was no histological evidence of inflammation or fibrosis. 
In addition, the integration rate with the surrounding cortex 
was significantly improved with anti-resorptive treatment.
 Local and systemic bisphosphonates are reported to 
reduce TRAP-positive cell numbers (Yu et al., 2010b) 
and this was also observed in the critical defect model. A 
group containing both bisphosphonate and HA particles 
was included as bisphosphonates have an affinity for 
calcium phosphate. This approach has been previously 
shown to delay ZA release (Yu et al., 2013). New insight 
has been obtained regarding the synergy between HA and 
bisphosphonate from a recent study using an alternative 
injectable delivery system. In this system HA microparticles 
were found to sequester bisphosphonate and delay its 
release. Moreover, in a cell culture model, the addition 
of HA microparticles provided cytoprotective effects 
against high dose bisphosphonate (Cheng et al., 2013). 
Pharmacological inhibition with PS-1145 demonstrates the 
potential use of IKK inhibitors as alternative anti-resorptive 
agents. IKK inhibition has been shown to suppress 
premature resorption in the repair of large bony defects 
through the inhibition of pathways necessary for osteoclast 
survival, differentiation, and function (von Metzler et al., 
2007). Combined with our recent results in an ectopic bone 
model (Carr et al., 2011), this study demonstrated further 
the utility of this agent in a more challenging defect model.
 One perceived limitation noted in this model was that 
the spatial control of bone formation was in some cases 
associated with poorer scaffold/cortex integration. This 
underlies reduced bone union in the PLGA + BMP group. 
We propose that a longer scaffold height that could be 
press fit to the defect would facilitate better integration 
between the PLGA implant and the original cortex. This, 
in combination with additional suturing to secure the 
implant further, could also reduce the rate of implant 
misalignment. Alternatively, we could envision a design 
where a cylinder slightly longer than the defect could be 
wrapped around the defect creating a region of overlap. 
One key advantage of a PLGA local delivery system is 
the capacity for increased control over the shape of the 
engineered bone by implanting custom-moulded scaffolds. 
Similar custom-shaping scaffold systems have been 
demonstrated with metal meshed scaffolds (Warnke et al., 
2004) and polymer/collagen hybrid sheet-based scaffolds 
(Tsuchiya et al., 2004).
Conclusion
This study demonstrated for the first time, the efficacy of 
using porous PLGA scaffold co-delivering rhBMP/ZA/
HA or rhBMP-2/PS-1145 to enhance rat critical defect 
healing. The synergistic anabolic and anti-resorptive 
effects of the local delivery system showed the potential 
to reduce the effective rhBMP-2 dose and to avoid the 
adverse events associated with local high rhBMP-2 
doses. Furthermore, incorporation of hydroxyapatite 
microparticles demonstrated a potential to augment the 
effects of ZA, and to lower the effective ZA drug dose 
required. Finally, this study demonstrated the efficacy of 
using porous PLGA scaffold for better spatial control of 
rhBMP-induced defect healing over collagen scaffold.
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Discussion with Reviewers
Reviewer I: The most interesting finding appears to be the 
spatial control. How would you quantify that? 
Authors: Spatial control is a broad term that encompasses 
the overall size of the regenerate (TV), descriptive 
illustration of the shape of the regenerate, and the 
integration of the regenerate with the original cortex. All of 
these methods are commonly reported for characterising a 
regenerate or fracture callus. Design of a novel metric for 
measuring spatial control is complex and would be open 
to debate. One potential quantifiable method would be to 
measure any regenerate tissue that extends beyond the 
original cortex in terms of a tissue volume (TV) amount. 
A more simplistic streamlined method is to simply take the 
existing regenerate TV values and subtract a cylindrical 
area equal to πR2H where R is half the average of the 
diameters at both ends of the bone defect and H is the 
height of the bone defect.
Reviewer I: In the collagen samples there seems to be a 
“hole” with no bone in the centre of the defect. What did 
you see there by histology?
Authors: These data are illustrated in Fig. 8 with the COL+ 
BMP figure being the most relevant to this question. This 
“bubble” region is not an area of inflammation – it is a 
region bounded by a thin cortex of bone with a marrow-
like space with some residual trabeculae. These findings 
are comparable to prior experiments published with ectopic 
bone formation models using these implants including Yu 
et al. (2013). Note that slower degrading polymer implants 
show residual polymer at these same time points, such as 
in Yu et al. (2010).
Reviewer I: An important problem with BMPs appears 
to be local inflammation and swelling, which probably 
is responsible for the more serious adverse events. You 
suggest that a slower release would remedy that. Is there 
any evidence for a change in “swelling/bone formation” 
ratio with lower concentrations?
Authors: The effects of BMPs on inflammation are 
certainly dose dependent, and there is a body of literature 
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to support this. One relevant study is by Lee et al. (2012). 
In this study both rhBMP-2 and rhBMP-7 are examined 
and shown to increase inflammatory cytokines in a dose 
dependent manner. Clinically, the complications associated 
with rhBMP use are associated with a strong initial 
inflammatory response. Thus we hypothesise that these 
problems may be minimised by a slower release system 
that mitigates early inflammation.
Reviewer II: The typical benefit of adding multiple 
therapies on a single platform is usually the reduction 
in dose of one of the therapeutics (in this case rhBMP-2 
with its known concerns). Why were groups with reduced 
rhBMP-2 doses not tested when anti-resorptive drugs 
were being used in conjunction since previous literature 
has apparently already tested BMP and bisphosphonates 
together?
Authors: The main rationale for this experimental design 
was to have appropriate controls. Having a lower rhBMP-2 
dose with anti-resorptives would mean that the effects of 
the different anti-resorptives could not be compared to a 
relevant control (i.e. the same dose of rhBMP-2 alone). 
One alternative/additional group that could have further 
demonstrated this point would have been a higher-dose 
rhBMP-2 group. However, the finding that a higher dose 
of rhBMP-2 would generate more bone would have been 
a fairly obvious outcome, and one that has been previously 
demonstrated.
Reviewer II: There is extensive peri-cortical callus 
response along the intact interfacial bone showing a robust 
regenerative response. Would the authors comment on any 
difference observed in the callus response between the 
different groups.
Authors: A greater peri-cortical response was found in 
the collagen (COL) scaffolds compared to PLGA scaffolds 
loaded with rhBMP-2. We hypothesise this is due to the 
superior implant interface osteointegration with COL 
scaffolds, leading to stimulation of the periosteum at the 
edge of the defect in those samples. This hypothesis will 
likely be confirmed in the future using PLGA implant 
designs that overlap with the original cortex, which should 
improve interface osteointegration.
Reviewer II: Sutures were threaded to the scaffolds to keep 
them in place. Despite this, a relatively high misalignment 
of scaffolds was observed (~10 %). Additionally, it is 
unclear if the collagen scaffolds were also similarly 
restrained. If they were restrained, what was the variation 
in the TV of the collagen + BMP sponges, or how 
inconsistently did they regenerate undesired ossification 
outside the defect region?
Authors: We also noted the ~10 % misalignment of the 
TIPS polymer scaffolds, which were sutured in place 
using a method also used for the collagen scaffolds. 
Collagen scaffolds created a bone mass that typically 
spanned the defect gap so misalignment was not apparent, 
which may reflect a potential advantage of collagen. In 
future, we would propose modifying our methodology to 
use additional sutures to more securely anchor the TIPS 
polymer scaffolds. For clinical translation we would also 
consider varying the design so as rather than using a solid 
cylindrical implant to be press fit in the defect, we would 
use a cylindrical tube that could wrap around and encircle 
the bone ends of the defect.
Reviewer III: Do you have any supporting data on the 
kinetics of drug release from your scaffolds?
Authors: We have previously looked at drug elution from 
these scaffolds in comparison with porous collagen. These 
data are published in Yu et al. (2013).
Reviewer III: Do you think there is strong evidence in the 
literature on the most appropriate rate of release for BMPs?
Authors: There is not strong evidence in the literature for 
an optimal rate of release of rhBMP-2. A minimal dose of 
rhBMP is required for induction of new bone, indicating 
that a certain degree of burst release is required. However, 
as previously discussed the inflammation associated with 
BMPs means that a slower release is an increasingly 
utilised strategy (Srouji et al., 2011; Wu et al., 2011).
Reviewer III: The PLGA material you used is fast 
degrading and others have expressed concerns about 
negative effects from degradation products. Do you think 
the literature is supportive of the use of this polymer class 
if it is restricted to use as a highly porous biomaterial 
within vascularised tissues? My group do not observe 
any problems with PLGA breakdown when we use highly 
porous scaffolds and we assume that the dose of acid by-
products is low compared to the tissue volume around the 
scaffold.
Authors: The presence of acidic breakdown products is 
an often cited concern. However, in practise this does not 
seem to translate into major problems for bone repair. In 
one of the first studies by Rokkanen et al. (1985), it was 
reported that a PLGA implant healed ankle fractures 5 d 
faster than conventional metal implants. However, it is 
possible that finding methods for reducing the low pH 
potentially created by PLGA implants may yield superior 
outcomes. One method for accomplishing this may be a 
bulk reduction in the amount of polymer by using a highly 
porous implant (such as we have done). In addition, others 
have incorporated other materials into PLGA to counter the 
acidic degradation products. Liu et al. (2006) investigated 
and showed this using titania nanoparticles. We propose 
that ceramic microparticles may be able to achieve a 
similar outcome, with ceramics being able to neutralise 
acidic biproducts.
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